Checkpoint Therapeutics Inc Cash Flow-to-Debt Ratio
Checkpoint Therapeutics Inc cash flow-to-debt ratio. Checkpoint Therapeutics Inc (CKPT) has a Cash Flow-to-Debt Ratio of -0.65x as of March 2025, meaning its operating cash flow of $-11.69 Million could theoretically repay -1% of its total liabilities ($17.87 Million) in one year. See Checkpoint Therapeutics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Checkpoint Therapeutics Inc (2015–2024)
Cash flow-to-debt ratio of Checkpoint Therapeutics Inc from 2015 to 2024. Historical debt coverage capacity for Checkpoint Therapeutics Inc across 10 annual periods. Check how aggressively does Checkpoint Therapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Checkpoint Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2024)
Checkpoint Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Checkpoint Therapeutics Inc. For the full cash flow conversion analysis, see Checkpoint Therapeutics Inc (CKPT) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.55x | $-31.10 Million | $20.10 Million | ▲ +40.1% |
| 2023 | -2.58x | $-47.59 Million | $18.43 Million | ▼ -47.1% |
| 2022 | -1.76x | $-57.55 Million | $32.77 Million | ▼ -73.5% |
| 2021 | -1.01x | $-26.31 Million | $25.98 Million | ▲ +55.9% |
| 2020 | -2.29x | $-16.55 Million | $7.22 Million | ▲ +12.9% |
| 2019 | -2.63x | $-21.37 Million | $8.12 Million | ▼ -33.6% |
| 2018 | -1.97x | $-25.80 Million | $13.09 Million | ▲ +18.8% |
| 2017 | -2.43x | $-15.46 Million | $6.37 Million | ▲ +10.4% |
| 2016 | -2.71x | $-9.95 Million | $3.67 Million | ▼ -941.0% |
| 2015 | -0.26x | $-1.11 Million | $4.26 Million | — |